National Centre for
Pharmacoeconomics
NCPE Ireland
About Us
Current Staff
News
Glossary
Contact Us
Vacancies
Home
Submission Process
HTA Guidelines
Process Flowchart
Submission Templates
Pharmacoeconomic Evaluations
Drugs
Vaccines
Diagnostics and Other Technologies
Publications
Peer Reviewed Papers
Abstracts
Reports
Research
Pharmacoeconomic Research
Education
COVID-19
For Patients
Drugs
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
R
S
T
U
V
Z
Ataluren (Translarna®)
Atezolizumab (Tecentriq® ) for Urothelial Carcinoma 2L
Atezolizumab (Tecentriq®)
Atezolizumab (Tecentriq®) for 1L NSCLC. HTA ID: 21012
Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036
Atezolizumab (Tecentriq®) for triple-negative breast cancer.
Atezolizumab (Tecentriq®) HTA ID: 20039
Atezolizumab (Tecentriq®) in combination with bevacizumab. HTA ID: 20060
Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide for 1L ES-SCLC HTA ID: 19030
Autologous anti-CD19-transduced CD3+ cells (Tecartus®). HTA ID: 21005
Previous Page
1
2
3
4
5
6
7
Next Page
health check